Tag: officer

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial (NCT05302037) (“ANGELICA Trial”) for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.

High-integrity carbon removal credits will be used to support buyer’s decarbonization and to mitigate corporate travel emissions

SAINT-BRUNO-DE-MONTARVILLE, Quebec, July 21, 2025 (GLOBE NEWSWIRE) -- Colabor Group Inc. (TSX: GCL) (“Colabor” or the “Company”) will release its results for the first quarter ended June 14, 2025, after market close on Thursday, July 24, 2025. A conference call to discuss these results will be held on Friday, July 25, 2025 at 9:30 a.m. (Eastern Time).

Tel Aviv, Israel, July 21, 2025 (GLOBE NEWSWIRE) -- Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, today announced the appointment of Mr. Eliyahu Zamir as the Company’s new Chief Executive Officer, effective as of August 1, 2025. Mr. Eliyahu Zamir will replace Mr. Viki Hakmon, who will step down from his position as the Company’s Chief Executive Officer, effective as of July 31, 2025. On July 21, 2025, Mr. Hakmon also resigned from the Board of Directors, effective immediately. Mr. Hakmon’s resignation did not result from any disagreements with the Company or the Board of Directors and he will continue to support the Company as a consultant of the Company’s subsidiary, Fort Products Limited.